Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials

Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials

Abstract Introduction Hidradenitis suppurativa (HS) is a chronic, painful skin disease associated with a high disease burden. Disease-related pain is frequently reported as the most troublesome symptom of HS. The SUNSHINE and SUNRISE phase 3 trials previously reported that secukinumab improved contr...

Full description

Saved in:
Bibliographic Details
Main Authors: John R. Ingram, Jacek C. Szepietowski, Lukasz Matusiak, Georgios Kokolakis, Magdalena B. Wozniak, Christine-Elke Ortmann, Angela Llobet Martinez, Shoba Ravichandran, Nicolas Thomas, Ivette Alarcon, Christelle C. Pieterse, Maryam Shayesteh Alam, Dimitrios Ioannides, Alexa B. Kimball
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-05-01
Series:Dermatology and Therapy
Subjects:
Acne inversa
Biologics
Hidradenitis suppurativa
HS
NRS
Pain control
Online Access:https://doi.org/10.1007/s13555-025-01426-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01426-x

Similar Items